The biology underlying the lower clinical response rates to immunotherapy in lung cancer with EGFR mutations has been investigated in several studies (13, 35) and is thought to be related to the higher diversity and lower clonality of patients with EGFR mutations. This evidence concerns the gene EGFR and lung carcinoma.